[ Price : $8.95]
HHS deputy general counsel Bob Fox Foster says FDAs chief counsel post will remain vacant until after president Trumps nominee, We...[ Price : $8.95]
FDA designates Formycons FYB202/Otulfi (ustekinumab-aauz) as an interchangeable biosimilar to Janssens reference biologic Stelara ...[ Price : $8.95]
FDA lifts a clinical hold against Scynexiss ibrexafungerp that will allow it to proceed with its Phase 3 MARIO study in invasive c...[ Price : $8.95]
FDA accepts for review a Travere Therapeutics supplemental NDA for traditional approval of Filspari (sparsentan) for treating foca...[ Price : $8.95]
FDA clears a Fujirebio Diagnostics 510(k) for the first in vitro diagnostic device that tests blood in diagnosing Alzheimers disea...[ Price : $8.95]
FDA posts briefing documents outlining issues to be discussed during a two-day (5/20-21) Oncologic Drugs Advisory Committee meetin...[ Price : $8.95]
FDA extends by two months its review of a PharmaTher NDA for Ketarx (ketamine) that is seeking anesthesia, sedation, pain, mental ...[ Price : $8.95]
FDA commissioner Marty Makary agrees to testify 5/22 at a Senate appropriations subcommittee hearing on the agencys fiscal year 20...